Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin

A total of 21 patients with advanced cancer were entered into a phase I study to determine the maximum tolerable dose (MTD) of liposome-encapsulated doxorubicin (LED) given weekly for 3 consecutive weeks at doses of 20, 30, or 37.5 mg/m2 per week. For a comparison of the pharmacokinetic behavior of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 1993-03, Vol.33 (2), p.107-112
Hauptverfasser:	CONLEY, B. A, EGORIN, M. J, WHITACRE, M. Y, CARTER, D. C, ZUHOWSKI, E. G, VAN ECHO, D. A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Chemotherapy Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - pharmacokinetics Drug Administration Schedule Drug Carriers Female Humans Liposomes Male Medical sciences Middle Aged Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!